

# Contents

|                                                                   |           |
|-------------------------------------------------------------------|-----------|
| <b>Contributors</b>                                               | <b>ix</b> |
| <b>Editor biography</b>                                           | <b>xi</b> |
| <b>1 Impact of diabetic retinopathy</b>                           | <b>1</b>  |
| Introduction                                                      | 1         |
| Macrovascular and microvascular complications                     | 1         |
| Diabetic retinopathy                                              | 3         |
| Conclusion                                                        | 9         |
| Key take-home messages                                            | 10        |
| References                                                        | 10        |
| <b>2 A basic scientific understanding of diabetic retinopathy</b> | <b>13</b> |
| Introduction                                                      | 13        |
| Polyol pathway                                                    | 15        |
| Advanced glycation end-products                                   | 16        |
| Protein kinase C activation                                       | 17        |
| Hemodynamic changes and RAAS system                               | 18        |
| Inflammation                                                      | 18        |
| Vascular endothelial growth factor                                | 19        |
| Reactive oxygen species                                           | 20        |
| Epigenetics                                                       | 20        |
| Conclusion                                                        | 22        |
| Key take-home messages                                            | 22        |
| References                                                        | 22        |
| <b>3 Diabetic retinopathy screening</b>                           | <b>25</b> |
| Introduction                                                      | 25        |
| Screening frequency and guidelines                                | 25        |
| Imaging                                                           | 27        |
| Key take-home messages                                            | 37        |
| References                                                        | 37        |

|          |                                                              |           |
|----------|--------------------------------------------------------------|-----------|
| <b>4</b> | <b>Medical management of diabetic retinopathy</b>            | <b>39</b> |
|          | Introduction                                                 | 39        |
|          | Glycated hemoglobin                                          | 40        |
|          | Improving microvascular outcomes: evidence from major trials | 41        |
|          | Macrovascular and cardiovascular outcomes                    | 43        |
|          | Diabetic retinopathy in pregnancy                            | 45        |
|          | Aspirin                                                      | 45        |
|          | Conclusion                                                   | 45        |
|          | Key take-home messages                                       | 46        |
|          | References                                                   | 46        |
| <b>5</b> | <b>Diabetes and cataracts</b>                                | <b>49</b> |
|          | Introduction                                                 | 49        |
|          | Lens changes in patients with diabetes                       | 51        |
|          | Management of diabetic cataracts                             | 52        |
|          | Key take-home messages                                       | 55        |
|          | References                                                   | 55        |
| <b>6</b> | <b>Diabetes and glaucoma</b>                                 | <b>59</b> |
|          | Introduction                                                 | 59        |
|          | Diabetes and primary open-angle glaucoma                     | 60        |
|          | Diabetes and neovascular glaucoma                            | 62        |
|          | Conclusion                                                   | 68        |
|          | Key take-home messages                                       | 69        |
|          | References                                                   | 69        |
| <b>7</b> | <b>Ocular surface disease in diabetes</b>                    | <b>71</b> |
|          | The problem                                                  | 71        |
|          | The mechanisms                                               | 71        |
|          | Patient evaluation                                           | 73        |
|          | Treatment                                                    | 75        |
|          | Key take-home messages                                       | 79        |
|          | References                                                   | 79        |

|                                                           |            |
|-----------------------------------------------------------|------------|
| <b>8 Management of diabetic macular edema</b>             | <b>81</b>  |
| Introduction                                              | 81         |
| Focal laser photocoagulation                              | 84         |
| Anti-vascular endothelial growth factor                   | 86         |
| Steroid therapy                                           | 93         |
| Surgical management                                       | 98         |
| Medical management                                        | 99         |
| Conclusions                                               | 100        |
| Key take-home messages                                    | 100        |
| References                                                | 101        |
| <br>                                                      |            |
| <b>9 Management of proliferative diabetic retinopathy</b> | <b>105</b> |
| Introduction                                              | 105        |
| Background                                                | 105        |
| Prevention and treatment                                  | 109        |
| Conclusion                                                | 117        |
| Key take-home messages                                    | 118        |
| References                                                | 118        |
| <br>                                                      |            |
| <b>10 Future therapies</b>                                | <b>121</b> |
| Introduction                                              | 121        |
| New laser technologies                                    | 121        |
| New pharmacological therapies                             | 123        |
| Conclusions                                               | 129        |
| References                                                | 131        |

Managing Diabetic Eye Disease in Clinical Practice

Singh, R. (Ed.)

2015, XI, 133 p. 44 illus., 38 illus. in color., Softcover

ISBN: 978-3-319-08328-5